Stoke Therapeutics Inc
STOK13.030USD
+0.120+0.93%
交易中 （美东）报价延迟15分钟
711.38M总市值
14.15市盈率 TTM
关于 Stoke Therapeutics Inc 公司
Stoke Therapeutics, Inc. 是一家生物技术公司，致力于通过使用基于核糖核酸 (RNA) 的药物上调蛋白质表达来解决严重疾病的根本原因。该公司通过其专有的靶向增强核基因输出 (TANGO) 方法，致力于开发反义寡核苷酸 (ASO) 以选择性恢复蛋白质水平。其首款化合物 STK-001 正在进行临床试验，用于治疗 Dravet 综合征，这是一种严重的渐进性遗传性癫痫。TANGO 旨在通过增加或刺激健康基因的蛋白质输出来恢复缺失的蛋白质，从而补偿无功能的基因副本。该公司正在开发 STK-002，用于治疗最常见的遗传性视神经疾病常染色体显性视神经萎缩 (ADOA)。该公司的初始重点是单倍体不足以及中枢神经系统和眼睛疾病。
公司简介
公司代码STOK
公司名称Stoke Therapeutics Inc
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
员工数量128
证券类型Ordinary Share
年结日Jun 19
公司地址45 Wiggins Avenue
城市BEDFORD
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编01730
电话17814308200
网址https://www.stoketherapeutics.com/
公司代码STOK
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
公司高管
名称
名称/职务
职务
持股
持股变动
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
139.35K
+43.83%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.83K
+55.93%
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
Mr. Thomas Leggett
Mr. Thomas Leggett
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
139.35K
+43.83%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
25.83K
+55.93%
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
158.57M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月31日 周四
更新时间: 7月31日 周四
持股股东
股东类型
持股股东
持股股东
占比
Lynx1 Capital Advisors LLC
9.69%
RTW Investments L.P.
9.38%
Baker Bros. Advisors LP
8.49%
Redmile Group, LLC
8.22%
Skorpios Trust
5.96%
Other
58.26%
持股股东
持股股东
占比
Lynx1 Capital Advisors LLC
9.69%
RTW Investments L.P.
9.38%
Baker Bros. Advisors LP
8.49%
Redmile Group, LLC
8.22%
Skorpios Trust
5.96%
Other
58.26%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
42.57%
Investment Advisor
42.51%
Research Firm
15.81%
Hedge Fund
13.38%
Individual Investor
4.63%
Sovereign Wealth Fund
0.58%
Bank and Trust
0.21%
Pension Fund
0.16%
Venture Capital
0.07%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
299
62.92M
115.25%
-5.63M
2025Q1
306
66.97M
122.66%
-2.21M
2024Q4
301
61.22M
115.58%
-8.44M
2024Q3
297
61.15M
115.51%
-9.18M
2024Q2
284
64.23M
122.75%
+5.19M
2024Q1
273
57.18M
122.36%
+3.72M
2023Q4
261
48.04M
104.80%
-6.40M
2023Q3
264
46.81M
105.69%
-6.29M
2023Q2
260
49.41M
111.78%
-2.48M
2023Q1
272
47.84M
108.41%
-17.61M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lynx1 Capital Advisors LLC
5.29M
9.69%
+104.74K
+2.02%
Mar 31, 2025
RTW Investments L.P.
5.12M
9.38%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
4.63M
8.49%
--
--
Mar 31, 2025
Redmile Group, LLC
4.49M
8.22%
-107.65K
-2.34%
Mar 31, 2025
Skorpios Trust
3.26M
5.96%
-3.65M
-52.85%
Jun 18, 2025
Morgan Stanley & Co. LLC
3.22M
5.89%
+255.18K
+8.62%
Mar 31, 2025
TD Securities, Inc.
3.17M
5.81%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.18%
+1.23K
+0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.78M
5.09%
+53.00K
+1.95%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.47M
4.52%
+2.30M
+1394.59%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
WisdomTree BioRevolution Fund
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Global X Genomics & Biotechnology ETF
0.61%
ALPS Medical Breakthroughs ETF
0.42%
iShares Health Innovation Active ETF
0.34%
Fidelity Fundamental Small-Mid Cap ETF
0.16%
SPDR S&P Biotech ETF
0.15%
iShares Micro-Cap ETF
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
ProShares Ultra Nasdaq Biotechnology
0.07%
查看更多
WisdomTree BioRevolution Fund
占比1.16%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
Global X Genomics & Biotechnology ETF
占比0.61%
ALPS Medical Breakthroughs ETF
占比0.42%
iShares Health Innovation Active ETF
占比0.34%
Fidelity Fundamental Small-Mid Cap ETF
占比0.16%
SPDR S&P Biotech ETF
占比0.15%
iShares Micro-Cap ETF
占比0.11%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.08%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
